CN Patent

CN117752813A — 抗cd33抗体和抗cd33抗体-药物偶联物及其用途

Assigned to Chengdu Bailidote Biological Pharmaceutical Co ltd · Expires 2024-03-26 · 2y expired

What this patent protects

本发明公开了抗CD33抗体和抗CD33抗体‑药物偶联物及其用途，具体公开了抗CD33抗体和/或其抗原结合片段，包括抗体‑药物偶联物和/或连接子药物或其立体异构体、药学上可接受的盐或溶剂化物的药物组合物，以及在治疗肿瘤或癌症中的用途。

USPTO Abstract

本发明公开了抗CD33抗体和抗CD33抗体‑药物偶联物及其用途，具体公开了抗CD33抗体和/或其抗原结合片段，包括抗体‑药物偶联物和/或连接子药物或其立体异构体、药学上可接受的盐或溶剂化物的药物组合物，以及在治疗肿瘤或癌症中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN117752813A
Jurisdiction
CN
Classification
—
Expires
2024-03-26
Drug substance claim
No
Drug product claim
No
Assignee
Chengdu Bailidote Biological Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.